Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.
Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes.
Additionally, Dr Jon Roffey joins Glythera’s scientific advisory board (SAB) from Cancer Research Technology (CRT), Cancer Research UK’s commercial partnerships team, where he had been working since 2006.
Dr Dave Simpson, chief executive officer of Glythera, said: “Robert Lutz’s experience in ADC development will be a great asset as Glythera continued to develop our pipeline of cancer treatments.
“With his appointment as CSO, and the addition of Jon to our SAD, we start 2018 in a strengthened position as developers of the very best novel agents and targeted treatments, aiming to improve the lives of patients living with cancers that are the hardest to treat.”
The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...